chloroquine has been researched along with Renal Insufficiency, Chronic in 4 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
Excerpt | Relevance | Reference |
---|---|---|
" This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD." | 2.66 | Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. ( Govil, A; Luckett, K; Miller-Handley, H, 2020) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 3 (75.00) | 2.80 |
Authors | Studies |
---|---|
Yang, C | 1 |
Wu, HL | 1 |
Li, ZH | 1 |
Chen, XC | 1 |
Su, HY | 1 |
Guo, XY | 1 |
An, N | 1 |
Jing, KP | 1 |
Pan, QJ | 1 |
Liu, HF | 1 |
Nachega, JB | 1 |
Ishoso, DK | 1 |
Otokoye, JO | 1 |
Hermans, MP | 1 |
Machekano, RN | 1 |
Sam-Agudu, NA | 1 |
Bongo-Pasi Nswe, C | 1 |
Mbala-Kingebeni, P | 1 |
Madinga, JN | 1 |
Mukendi, S | 1 |
Kolié, MC | 1 |
Nkwembe, EN | 1 |
Mbuyi, GM | 1 |
Nsio, JM | 1 |
Mukeba Tshialala, D | 1 |
Tshiasuma Pipo, M | 1 |
Ahuka-Mundeke, S | 1 |
Muyembe-Tamfum, JJ | 1 |
Mofenson, L | 1 |
Smith, G | 1 |
Mills, EJ | 1 |
Mellors, JW | 1 |
Zumla, A | 1 |
Mavungu Landu, DJ | 1 |
Kayembe, JM | 1 |
Miller-Handley, H | 1 |
Luckett, K | 1 |
Govil, A | 1 |
Fox, C | 1 |
Cocchiaro, P | 1 |
Oakley, F | 1 |
Howarth, R | 1 |
Callaghan, K | 1 |
Leslie, J | 1 |
Luli, S | 1 |
Wood, KM | 1 |
Genovese, F | 1 |
Sheerin, NS | 1 |
Moles, A | 1 |
1 review available for chloroquine and Renal Insufficiency, Chronic
Article | Year |
---|---|
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanize | 2020 |
3 other studies available for chloroquine and Renal Insufficiency, Chronic
Article | Year |
---|---|
Autophagy Inhibition Sensitizes Renal Tubular Epithelial Cell to G1 Arrest Induced by Transforming Growth Factor beta (TGF-β).
Topics: Autophagy; Cell Line; Cell Proliferation; Chloroquine; Cyclin-Dependent Kinase 4; Cyclin-Dependent K | 2020 |
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatme | 2020 |
Inhibition of lysosomal protease cathepsin D reduces renal fibrosis in murine chronic kidney disease.
Topics: Animals; Cathepsin D; Chloroquine; Collagen; Dipeptides; Disease Models, Animal; Extracellular Matri | 2016 |